We are live on ! Find out more

AEON Biopharma

AEON

Market cap $15M

0.3000 USD

+0.0410

15.83%

At close Updated Sep 30, 4:00 PM EDT

Pre-market

After hours

0.3000

0.0000

0%

1 day

15.83%

5 days

13.12%

1 month

1.39%

3 months

-58.29%

6 months

-69.68%

Year to date

-72.97%

1 year

-62.9%

5 years

-99.96%

10 years

-99.96%

About: AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.

Employees: 8

Healthcare Drug Manufacturers - General

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450

FDA indicated previously completed ABP-450 head-to-head studies versus BOTOX® may be submitted as supportive evidence; AEON expects to advance the required scientific bridging work AEON plans to submit an IND for CMAP pharmacodynamic study in the fourth quarter of 2026 AEON plans to leverage its analytical, pharmacodynamic, and existing comparative human evidence to support a potential streamlined development path ALISO VIEJO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced receipt of the official minutes from its Biosimilar Biological Product Development (“BPD”) Type 2b meeting held with the U.S. Food and Drug Administration (“FDA” or the “Agency”) regarding ABP-450's development pathway.

AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450

AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX®

ABP-450 and BOTOX® demonstrated comparable rates of potency loss under thermal stress and similar site-specific oxidation patterns across methionine sites evaluated Results provide additional analytical evidence supporting comparability and establish the basis for AEON's planned multi-lot comparability study ALISO VIEJO, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX ® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced positive results from a pilot forced degradation study comparing ABP-450 to BOTOX ® under thermal and oxidative stress conditions.

AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX®

AEON Biopharma to Participate in Lake Street Capital Markets' 10th Annual Best Ideas Growth (BIG10) Conference

ALISO VIEJO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, announced today that AEON management will host in-person 1x1 investor meetings at Lake Street Capital Markets' 10th Annual Best Ideas Growth (BIG10) Conference being held in New York City on Thursday, September 10th, 2026.

AEON Biopharma to Participate in Lake Street Capital Markets' 10th Annual Best Ideas Growth (BIG10) Conference

AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer

- Former Deputy Director of the FDA's Office of Neuroscience - Dr. Lee has previously advised AEON through Clintrex Research LLC (Clintrex), an affiliate of BlueRidge Life Sciences, on the regulatory strategy for ABP-450 ALISO VIEJO, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced the designation of Paul Lee, M.D.

AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer

AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX®

- Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin primary sequence from approximately 93% to 98%, with 100% amino acid identity across all regions analyzed

AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX®

AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

- Executed a $15.3 million financing with milestone warrants providing potential for an additional $34.0 million in gross proceeds, supporting continued advancement of ABP-450's development program

AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards

ALISO VIEJO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced that it has received written notice from NYSE American LLC (“NYSE American”) confirming that AEON has regained compliance with NYSE American's continued listing standards relating to stockholders' equity.

AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards

Bitget Launchpool adds AEON (AEON) with 1.1M in Token Rewards

VICTORIA, Seychelles, July 27, 2026 (GLOBE NEWSWIRE) -- Bitget , the world's largest Universal Exchange (UEX), announced the addition of AEON (AEON) to Bitget Launchpool and spot market. Spot trading for the AEON/USDT pair opens on July 27, 2026, 11:00 (UTC), with withdrawals available from July 28, 2026, 12:00 (UTC).

Bitget Launchpool adds AEON (AEON) with 1.1M in Token Rewards

AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding

$13.75 million underwritten public offering with up to an additional $29.6 million in potential proceeds tied to the cash exercise in full of the milestone warrants issued in the offering $13.75 million underwritten public offering with up to an additional $29.6 million in potential proceeds tied to the cash exercise in full of the milestone warrants issued in the offering

AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding

AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society

IRVINE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced the presentation of new analytical and functional data supporting biosimilarity of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society (“AHS”), being held June 4-7, 2026 in Orlando, Florida. The poster is being presented by Chad K. Oh, M.D., AEON's Chief Medical Officer.

AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society

See News Rankings

Price charts implemented using Lightweight Charts™